FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000594485> ?p ?o ?g. }

• W2000594485 endingPage "9968" @default.
• W2000594485 startingPage "9962" @default.
• W2000594485 abstract "We have previously reported on the death effector domain containing E8 gene product from equine herpesvirus-2, designated FLICE inhibitory protein (v-FLIP), and on its cellular homologue, c-FLIP, which inhibit the activation of caspase-8 by death receptors. Here we report on the structure and function of the E10 gene product of equine herpesvirus-2, designated v-CARMEN, and on its cellular homologue, c-CARMEN, which contain a caspase-recruiting domain (CARD) motif. c-CARMEN is highly homologous to the viral protein in its N-terminal CARD motif but differs in its C-terminal extension. v-CARMEN and c-CARMEN interact directly in a CARD-dependent manner yet reveal different binding specificities toward members of the tumor necrosis factor receptor-associated factor (TRAF) family. v-CARMEN binds to TRAF6 and weakly to TRAF3 and, upon overexpression, potently induces the c-Jun N-terminal kinase (JNK), p38, and nuclear factor (NF)-κB transcriptional pathways. c-CARMEN or truncated versions thereof do not appear to induce JNK and NF-κB activation by themselves, nor do they affect the JNK and NF-κB activating potential of v-CARMEN. Thus, in contrast to the cellular homologue, v-CARMEN may have additional properties in its unique C terminus that allow for an autonomous activator effect on NF-κB and JNK. Through activation of NF-κB, v-CARMEN may regulate the expression of the cellular and viral genes important for viral replication. We have previously reported on the death effector domain containing E8 gene product from equine herpesvirus-2, designated FLICE inhibitory protein (v-FLIP), and on its cellular homologue, c-FLIP, which inhibit the activation of caspase-8 by death receptors. Here we report on the structure and function of the E10 gene product of equine herpesvirus-2, designated v-CARMEN, and on its cellular homologue, c-CARMEN, which contain a caspase-recruiting domain (CARD) motif. c-CARMEN is highly homologous to the viral protein in its N-terminal CARD motif but differs in its C-terminal extension. v-CARMEN and c-CARMEN interact directly in a CARD-dependent manner yet reveal different binding specificities toward members of the tumor necrosis factor receptor-associated factor (TRAF) family. v-CARMEN binds to TRAF6 and weakly to TRAF3 and, upon overexpression, potently induces the c-Jun N-terminal kinase (JNK), p38, and nuclear factor (NF)-κB transcriptional pathways. c-CARMEN or truncated versions thereof do not appear to induce JNK and NF-κB activation by themselves, nor do they affect the JNK and NF-κB activating potential of v-CARMEN. Thus, in contrast to the cellular homologue, v-CARMEN may have additional properties in its unique C terminus that allow for an autonomous activator effect on NF-κB and JNK. Through activation of NF-κB, v-CARMEN may regulate the expression of the cellular and viral genes important for viral replication. FLICE inhibitory protein caspase-recruiting domain CARD-containing molecule enhancing NF-κB death effector domain equine herpesvirus-2 extracellular signal-regulated kinase IκB kinase c-Jun N-terminal kinase nuclear factor tumor necrosis factor receptor-associated factor open reading frame dominant negative hemagglutinin expressed sequence tag vesicular stomatitis virus The ability to undergo apoptosis is an inherent property of all somatic cells. Apoptosis can be triggered by a variety of stimuli, such as ligands of the tumor necrosis factor family, cytotoxic drugs, growth factor starvation, and infectious agents such as viruses. Viruses are faced with the need to productively replicate within a receptive intracellular environment and thus have evolved strategies to counteract the death signaling machinery (1McFadden G. Lalani A. Everett H. Nash P. Xu X. Semin. Cell Dev. Biol. 1998; 9: 359-368Crossref PubMed Scopus (60) Google Scholar, 2Tschopp J. Thome M. Hofmann K. Meinl E. Curr. Opin. Genet. Dev. 1998; 8: 82-87Crossref PubMed Scopus (176) Google Scholar). Documented viral apoptosis inhibitors include proteins that have a bcl-2-like function or those that directly interfere with caspase activity. We and others (3Thome M. Schneider P. Hofmann K. Fickenscher H. Meinl E. Neipel F. Mattmann C. Burns K. Bodmer J.L. Schroter M. Scaffidi C. Krammer P.H. Peter M.E. Tschopp J. Nature. 1997; 386: 517-521Crossref PubMed Scopus (1145) Google Scholar, 4Bertin J. Armstrong R.C. Ottilie S. Martin D.A. Wang Y. Banks S. Wang G.H. Senkevich T.G. Alnemri E.S. Moss B. Lenardo M.J. Tomaselli K.J. Cohen J.I. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 1172-1176Crossref PubMed Scopus (384) Google Scholar, 5Hu S. Vincenz C. Buller M. Dixit V.M. J. Biol. Chem. 1997; 272: 9621-9624Abstract Full Text Full Text PDF PubMed Scopus (268) Google Scholar) have recently characterized a family of viral gene products, collectively called v-FLIPs,1that are produced by many γ-herpesviruses and by the molluscum contagiosum virus. The striking structural feature of the viral FLIPs is the presence of a tandem repeat of a so-called death effector domain (DED). The DED has structural homology to a motif called the death domain, which is present in the cytoplasmic part of death receptors such as Fas. The death domain of Fas interacts with the C-terminal death domain of FADD, which in turn induces the binding of the N-terminal DED of FADD to the DED-containing prodomain of caspase-8. The recruitment and activation of caspase-8 by Fas result in the processing of downstream caspases and the induction of apoptosis (6Nagata S. Cell. 1997; 88: 355-365Abstract Full Text Full Text PDF PubMed Scopus (4561) Google Scholar). The DED-containing v-FLIPs interfere with the FADD-caspase-8 interaction and hence block apoptosis (3Thome M. Schneider P. Hofmann K. Fickenscher H. Meinl E. Neipel F. Mattmann C. Burns K. Bodmer J.L. Schroter M. Scaffidi C. Krammer P.H. Peter M.E. Tschopp J. Nature. 1997; 386: 517-521Crossref PubMed Scopus (1145) Google Scholar). Thus, the DED and the death domain are important protein-protein interaction modules implicated in cell death signaling. Recently, the existence of a third related protein-protein interaction domain, designated the caspase-recruiting domain (CARD), was revealed (7Hofmann K. Bucher P. Tschopp J. Trends Biochem. Sci. 1997; 22: 155-156Abstract Full Text PDF PubMed Scopus (450) Google Scholar). The prototype CARD is found in Apaf-1, a mitochondrial protein related to the Caenorhabditis elegans protein CED-4 (8Zou H. Henzel W.J. Liu X. Lutschg A. Wang X. Cell. 1997; 90: 405-413Abstract Full Text Full Text PDF PubMed Scopus (2745) Google Scholar). Activation of Apaf-1 by cytochrome c leads to the recruitment of the CARD-containing caspase-9 and to subsequent apoptosis (9Li P. Nijhawan D. Budihardjo I. Srinivasula S.M. Ahmad M. Alnemri E.S. Wang X. Cell. 1997; 91: 479-489Abstract Full Text Full Text PDF PubMed Scopus (6255) Google Scholar). Additional CARD-dependent protein interactions have been identified. The CARD-containing adaptor molecule RAIDD recruits caspase-2 to the tumor necrosis factor receptor 1 (10Duan H. Dixit V.M. Nature. 1997; 385: 86-89Crossref PubMed Scopus (469) Google Scholar), whereas the CARD-containing kinase CARDIAK/RIP-2 may mediate both the recruitment and activation of caspase-1 by CD40 and the activation of JNK and NF-κB (11Thome M. Hofmann K. Burns K. Martinon F. Bodmer J.L. Mattmann C. Tschopp J. Curr. Biol. 1998; 8: 885-888Abstract Full Text Full Text PDF PubMed Google Scholar, 12McCarthy J.V. Ni J. Dixit V.M. J. Biol. Chem. 1998; 273: 16968-16975Abstract Full Text Full Text PDF PubMed Scopus (369) Google Scholar). The respective recruiting/regulatory proteins of other CARD-containing caspases (caspase-4, -5, -11, and -12), are currently not known. Other CARD-containing proteins, i.e.ARC (13Koseki T. Inohara N. Chen S. Nunez G. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 5156-5160Crossref PubMed Scopus (311) Google Scholar), c-IAP1, and c-IAP2 (14Roy N. Deveraux Q.L. Takahashi R. Salvesen G.S. Reed J.C. EMBO J. 1997; 16: 6914-6925Crossref PubMed Scopus (1138) Google Scholar), are involved in the regulation of apoptosis. We have previously reported on a gene product from equine herpesvirus type 2 (EHV-2), designated E10, that comprises a CARD motif (7Hofmann K. Bucher P. Tschopp J. Trends Biochem. Sci. 1997; 22: 155-156Abstract Full Text PDF PubMed Scopus (450) Google Scholar). Because the E8 gene, which is found in the same region of the EHV-2 genome, encodes the potent apoptosis inhibitor v-FLIP, we undertook a study to investigate whether E10 may also be implicated in the modulation of apoptosis. The complete ORF of viral E10 was amplified from viral EHV-2 DNA (a kind gift of A. J. Davison, Glasgow, United Kingdom). The amplified E10 ORF is longer than the originally publishedE10 ORF (after resequencing of the respective region of the viral genome, we had to correct the originally reported E10sequence (15Telford E.A.R. Watson M.S. Aird H.C. Perry J. Davison A.J. J. Mol. Biol. 1995; 249: 520-528Crossref PubMed Scopus (185) Google Scholar) that predicted a shorter ORF). EST clones encoding a related human and mouse CARD-containing protein were identified in the dbEST data base at the National Center for Biotechnology Information (EST clones 703916 and 574273) by performing a data base search using a generalized profile method (16Bucher P. Karplus K. Moeri N. Hofmann K. Comput. Chem. 1996; 20: 3-24Crossref PubMed Scopus (257) Google Scholar) based on the sequence homology among other CARD-containing proteins (7Hofmann K. Bucher P. Tschopp J. Trends Biochem. Sci. 1997; 22: 155-156Abstract Full Text PDF PubMed Scopus (450) Google Scholar). Northern blot analysis was performed by probing a murine multiple tissue Northern blot (CLONTECH), according to the manufacturer's instructions, with a 32P-labeled antisense RNA probe encompassing the complete ORF of murine CARMEN cDNA. cDNAs encoding CARMEN proteins or fragments thereof were amplified by standard polymerase chain reaction methods using Pwo polymerase (Boehringer Mannheim) and specific primers containing suitable restriction sites on the 5′- and 3′-end on cDNA templates from the following sources. Full-length humanCARMEN (amino acids 2–233), a deletion construct encompassing the N-terminal CARD (amino acids 2–89, h-CARMEN-NT) or lacking the CARD (amino acids 85–233, h-CARMEN-CT), was amplified on EST clone 703916; full-length murine CARMEN (amino acids 2–233) was amplified on EST clone 574273; and full-length v-CARMEN was amplified on EHV-2 DNA. An internalBamHI site at nucleotide 412 of v-CARMEN was used for the construction of a C-terminally truncated v-CARMENencompassing the N-terminal CARD (amino acids 1–139, v-CARMEN-NT). A deletion construct lacking the CARD (amino acids 109–311, v-CARMEN-CT) was amplified on cloned full-length v-CARMEN. Amplified products were cloned into pCRblunt (Invitrogen) and sequenced. Subcloning into expression vectors derived from pCR-3 (Invitrogen) yielded expression constructs with an N-terminal FLAG, hemagglutinin (HA), or vesicular stomatitis virus (VSV) tag. For the yeast two-hybrid interaction assay, sequenced constructs of v-CARMEN, h-CARMEN, and their above described N-terminally truncated versions were subcloned into pGBT-9 or pGAD10 (CLONTECH), yielding GAL4-DNA-binding proteins or GAL4-activation-domain fusion proteins, respectively. The following expression plasmids were obtained from the indicated sources: NF-κBLuc (V. Jongeneel, Lausanne, Switzerland); FLAG-tagged JNK (C. Widmann, Denver, CO); HA-tagged p38 (J. S. Gutkind, NIDR, Bethesda, MD); ERK-1 (J. Pouysségur, Nice, France); dominant negative (DN) GFP-TRAF2 (amino acids 266–501) (H. Wajant, Stuttgart, Germany); DN TRAF6, wild type, and DN IKK2 (S. Whiteside and A. Israël, Paris, France); v-19 ras (E. Reichmann, Lausanne, Switzerland). These techniques were performed essentially as described before (11Thome M. Hofmann K. Burns K. Martinon F. Bodmer J.L. Mattmann C. Tschopp J. Curr. Biol. 1998; 8: 885-888Abstract Full Text Full Text PDF PubMed Google Scholar, 17Burns K. Martinon F. Esslinger C. Pahl H. Schneider P. Bodmer J.L. Di Marco F. French L. Tschopp J. J. Biol. Chem. 1998; 273: 12203-12209Abstract Full Text Full Text PDF PubMed Scopus (521) Google Scholar, 18Bodmer J.L. Burns K. Schneider P. Hofmann K. Steiner V. Thome M. Bornand T. Hahne M. Schroter M. Becker K. Wilson A. French L.E. Browning J.L. MacDonald H.R. Tschopp J. Immunity. 1997; 6: 79-88Abstract Full Text Full Text PDF PubMed Scopus (242) Google Scholar). Activation of p38 and ERK-1 was detected using phosphospecific antibodies that detect the active form of the respective mitogen-activated protein kinases (New England Biolabs). Protein-protein interactions were analyzed by cotransforming a plasmid encoding a v-CARMEN-GAL4-DNA-binding (GAL4-DB) fusion protein with plasmids encoding various v/h-CARMEN-GAL4-activation-domain fusion protein constructs (2.5 μg of each plasmid) into the Saccharomyces cerevisiae strain Y190 and subsequent filter lift assays for colony color development according to the manufacturer's instructions (CLONTECH, yeast protocols handbook). Controls were performed by using the respective vectors without insert. To study the possible physiological role of the viral E10 gene product, designated v-CARMEN (for CARD-containingmolecule enhancing NF-κB, see below), we assessed effector functions that have been described for other CARD-containing proteins such as modulation of apoptosis and activation of JNK and NF-κB. Expression constructs encoding v-CARMEN and a number of proapoptotic proteins were transfected into 293T cells, and the presence of apoptotic cells was subsequently analyzed. Although overexpression of v-CARMEN was very weakly cytotoxic, expression of Fas, DR-3/TRAMP, TRAIL-R1, or TRAIL-R2 lead to extensive cell death, which was neither inhibited nor enhanced by the coexpression of v-CARMEN (data not shown). Stable transfection of Jurkat cells with v-CARMEN or a construct lacking the CARD motif did not alter the cells' susceptibility to Fas or staurosporine-induced apoptosis (data not shown). Next we tested whether v-CARMEN was able to stimulate activation of JNK by coexpressing v-CARMEN with JNK in 293T cells. Activation of JNK leads to its phosphorylation by upstream kinases, which can be detected by antibodies specifically recognizing the phosphorylated but not the unphosphorylated form of JNK. Compared with the vector control, v-CARMEN potently induced JNK activation (Fig.1 A). Activation of the kinase appeared to be dependent on the CARD motif, because overexpression of the C-terminal part of v-CARMEN (lacking the CARD) did not result in increased JNK activation, whereas a C-terminally truncated construct encompassing the CARD (v-CARMEN-NT) was able to induce some JNK activation. v-CARMEN-induced JNK activation was not inhibited by dominant negative versions of TRAF2 or apoptosis signal-regulating kinase 1 (ASK 1) (data not shown), indicating that v-CARMEN acts downstream or independently of these mediators of tumor necrosis factor-induced JNK activation (19Nishitoh H. Saitoh M. Mochida Y. Takeda K. Nakano H. Rothe M. Miyazono K. Ichijo H. Mol. Cell. 1998; 2: 389-395Abstract Full Text Full Text PDF PubMed Scopus (579) Google Scholar). v-CARMEN also activated the stress kinase p38 in a CARD-dependent manner (Fig. 1 B). In contrast, no activation of the MAP kinase ERK-1 was seen by the overexpression of the viral protein (Fig. 1 C). The ability of v-CARMEN to activate an NF-κB luciferase reporter plasmid was next investigated. Expression of v-CARMEN in 293T cells resulted in a dose-dependent activation of the reporter gene, reaching an approximately 10-fold increase in luciferase activity as compared with the vector control (Fig. 1, D andE). Induction of NF-κB activity by v-CARMEN was almost as strong as that seen with the adaptor protein MyD88 (Fig.1 D), which links interleukin-1R and toll receptors to NF-κB signaling pathways (17Burns K. Martinon F. Esslinger C. Pahl H. Schneider P. Bodmer J.L. Di Marco F. French L. Tschopp J. J. Biol. Chem. 1998; 273: 12203-12209Abstract Full Text Full Text PDF PubMed Scopus (521) Google Scholar, 20Wesche H. Henzel W.J. Shillinglaw W. Li S. Cao Z. Immunity. 1997; 7: 837-847Abstract Full Text Full Text PDF PubMed Scopus (922) Google Scholar, 21Muzio M. Ni J. Feng P. Dixit V.M. Science. 1997; 278: 1612-1615Crossref PubMed Scopus (987) Google Scholar, 22Muzio M. Natoli G. Saccani S. Levrero M. Mantovani A. J. Exp. Med. 1998; 187: 2097-2101Crossref PubMed Scopus (527) Google Scholar). Similar to the requirement for JNK activation, the initiation of NF-κB signals by v-CARMEN was dependent on the presence of the CARD motif. Activation of NF-κB is dependent on the formation of a multiprotein complex, which is comprised of TRAFs, the NF-κB-inducing kinase (NIK), IKK1, IKK2, the NF-κB essential modulator (NEMO), IκBα, IκBβ, and the IKK-complex-associated protein (ICAP) (23Scheidereit C. Nature. 1998; 395: 225-226Crossref PubMed Scopus (55) Google Scholar). Dominant negative versions of some of these proteins can block NF-κB-activating signals triggered by upstream receptors. Indeed, DN IKK2, but not DN TRAF2 or DN TRAF6, inhibited v-CARMEN-mediated NF-κB activation, indicating that the overexpression of the viral protein initiated a signal cascade downstream of TRAFs but upstream of IKK2 in the NF-κB signaling complex (Fig. 1 F and data not shown). CARDs are known to serve as protein-protein interaction motifs (9Li P. Nijhawan D. Budihardjo I. Srinivasula S.M. Ahmad M. Alnemri E.S. Wang X. Cell. 1997; 91: 479-489Abstract Full Text Full Text PDF PubMed Scopus (6255) Google Scholar, 10Duan H. Dixit V.M. Nature. 1997; 385: 86-89Crossref PubMed Scopus (469) Google Scholar). It was therefore likely that v-CARMEN exerted its JNK and NF-κB activating effects through association with another CARD-containing protein. In this regard, by screening public data bases with a CARD sequence profile (7Hofmann K. Bucher P. Tschopp J. Trends Biochem. Sci. 1997; 22: 155-156Abstract Full Text PDF PubMed Scopus (450) Google Scholar, 16Bucher P. Karplus K. Moeri N. Hofmann K. Comput. Chem. 1996; 20: 3-24Crossref PubMed Scopus (257) Google Scholar) we discovered the presence of a novel CARD protein with high homology to the CARD motif of v-CARMEN, which we call c-CARMEN (Fig. 2 A). v-CARMEN corresponds to a 311-amino acid protein with an N-terminal CARD motif followed by a C-terminal, glycine-rich extension of approximately 200 amino acid residues. After the resequencing of this region of the viral genome, we had to correct the original E10 sequence deposited in the data base, which predicted a shorter ORF corresponding to only 210 amino acids (15Telford E.A.R. Watson M.S. Aird H.C. Perry J. Davison A.J. J. Mol. Biol. 1995; 249: 520-528Crossref PubMed Scopus (185) Google Scholar). The predicted protein size of the corrected 311-amino acid v-CARMEN (34 kDa) agrees well with the 36-kDa protein detectable after expression in 293T cells (see Fig. 1). c-CARMEN (the cellular homologue of v-CARMEN) consists of an N-terminal CARD followed by a C-terminal extension of approximately 130 amino acids with a predicted molecular size of 26 kDa. The CARD of v-CARMEN shows 47 and 46% sequence identity with mouse and human c-CARMEN, respectively, but only approximately 20–25% sequence identity with other CARD-containing proteins (Fig. 2 B). Little sequence identity is found in the C-terminal extensions of the viral and the cellular CARMEN, the latter of which lacks the glycine-rich regions. Neither of the C-terminal extensions has significant homology to protein sequences currently found in public data bases. Northern blot analysis revealed that murine CARMEN(m-CARMEN) was expressed in all mouse tissues as a single transcript of approximately 2.4 kilobases (Fig.3), suggesting that the protein is of functional relevance in many cell types. The potential interaction of c-CARMEN with other CARD-containing proteins was examined by coexpression of the different FLAG-tagged CARD proteins with HA-tagged human CARMEN (h-CARMEN) in 293T cells followed by co-immunoprecipitation studies. Using this technique, an interaction was noted only between v-CARMEN and h-CARMEN, whereas caspase-1, -2, -4, and -9, RAIDD, or CARDIAK did not interact with h-CARMEN (Fig.4 A). We also did not detect an interaction with the CARD motif of Apaf-1, cIAP-1, or cIAP-2 (data not shown). A truncated version of v-CARMEN lacking the CARD motif (v-CARMEN-CT) did not interact with either human or mouse c-CARMEN, indicating that binding was mediated through the CARD motif (Fig.4 B). An analysis of this interaction in the yeast two-hybrid system confirmed a direct and CARD-dependent interaction of v-CARMEN with h-CARMEN (Table I). Interestingly, c-CARMEN of human and mouse origin also formed CARD-dependent homodimers in 293T cells (Fig.4 B). We were unable to detect homodimers of v-CARMEN in 293T cells, although a homodimeric interaction of v-CARMEN was detected in the yeast two-hybrid system (Table I). Interestingly, the interaction between v-CARMEN and its cellular homologue lead to an altered electrophoretic mobility of the c-CARMENs (Fig. 4 B). Human and murine CARMEN migrated slightly slower by SDS-polyacrylamide gel electrophoresis in the presence of v-CARMEN, suggesting that the cellular homologue may undergo a post-translational modification such as phosphorylation upon interaction with the viral homologue. Whether this is because of the JNK/IKK kinase-inducing activity of v-CARMEN (potentially recruiting kinases to the complex of viral/cellular CARMEN) remains to be seen.Table ICARD-dependent interaction of v- and h-CARMEN in the yeast two-hybrid systemDBADh-CARMENh-CARMEN-CTv-CARMENv-CARMEN-CTControlv-CARMEN++−++−−Control−−−−−Viral and human CARMEN or C-terminal (CT) constructs thereof lacking the CARD were expressed in yeast as GAL4 DNA binding (DB) or GAL4 activation domain (AD) fusion proteins and were tested for interaction by a filter lift β-galactosidase color assay. (++) indicates blue color development within 30 min, (−) indicates no color development even after 6 h. Controls were performed using the respective expression vectors without insert. Open table in a new tab Viral and human CARMEN or C-terminal (CT) constructs thereof lacking the CARD were expressed in yeast as GAL4 DNA binding (DB) or GAL4 activation domain (AD) fusion proteins and were tested for interaction by a filter lift β-galactosidase color assay. (++) indicates blue color development within 30 min, (−) indicates no color development even after 6 h. Controls were performed using the respective expression vectors without insert. Because v-CARMEN was a potent activator of the JNK and NF-κB signaling pathways, we anticipated a similar function for the cellular homologue. However, overexpression of either full-length c-CARMEN or of domains thereof was not capable of activating these signaling pathways in 293T cells (Fig. 5, A andB, and data not shown). c-CARMEN and its N- or C-terminal deletion constructs also did not inhibit NF-κB or JNK signals induced by v-CARMEN or by triggering the receptors for tumor necrosis factor or interleukin-1 (data not shown), indicating that the cellular homologue is not essential to these pathways. We considered that the difference in signaling by v-CARMENversus c-CARMEN might be because of their ability to interact with specific TRAF molecules, because members of the TRAF family of adaptor proteins have been shown to be implicated in the activation of transcription through JNK- and NF-κB-dependent pathways (reviewed in Ref. 24Arch R.H. Gedrich R.W. Thompson C.B. Genes Dev. 1998; 12: 2821-2830Crossref PubMed Scopus (518) Google Scholar). We therefore tested the ability of c-CARMEN and v-CARMEN to bind to specific members of the TRAF family by coexpression of the respective proteins in 293T cells. The result of the co-precipitation study shown in Fig. 5 revealed a clear difference in the TRAF binding specificity of c-CARMEN and v-CARMEN; human CARMEN bound specifically to TRAF1 and TRAF5, whereas the v-CARMEN had a clear binding preference for TRAF6 and, to a smaller degree, for TRAF3 (Fig. 5, C andD). EHV-2 is a slow growing, cytopathogenic γ-herpesvirus, which appears to be ubiquitous in the equine population (15Telford E.A.R. Watson M.S. Aird H.C. Perry J. Davison A.J. J. Mol. Biol. 1995; 249: 520-528Crossref PubMed Scopus (185) Google Scholar). However, its precise role as a pathogen remains uncertain. In infected horses, the virus can induce chronic pharyngitis associated with lymphoid proliferation (25Blakeslee Jr., J.R. Olsen R.G. McAllister E.S. Fassbender J. Dennis R. Can. J. Microbiol. 1975; 21: 1940-1946Crossref PubMed Scopus (60) Google Scholar). The virus is persistent in peripheral blood lymphocytes, suggesting that it copes well with apoptotic processes occurring in the host. We have previously identified its DED-containing E8 gene product (v-FLIP) as a potent inhibitor of the death receptor-signaling pathways (3Thome M. Schneider P. Hofmann K. Fickenscher H. Meinl E. Neipel F. Mattmann C. Burns K. Bodmer J.L. Schroter M. Scaffidi C. Krammer P.H. Peter M.E. Tschopp J. Nature. 1997; 386: 517-521Crossref PubMed Scopus (1145) Google Scholar). Moreover, EHV-2 also has a predicted bcl-2 gene homologue in its genome (2Tschopp J. Thome M. Hofmann K. Meinl E. Curr. Opin. Genet. Dev. 1998; 8: 82-87Crossref PubMed Scopus (176) Google Scholar). Although its biological activity has not yet been verified, it is predicted that the gene product of this viralbcl-2 homologue inhibits apoptotic signals originating from the Apaf-1/caspase-9 pathway. In this report we have characterized the EHV-2 protein E10, designated v-CARMEN, as a potent inducer of the NF-κB and JNK pathways. Cellular gene products induced by the NF-κB transcription factor are known to inhibit apoptosis by a variety of means (26Wang C.Y. Mayo M.W. Korneluk R.G. Goeddel D.V. Baldwin Jr., A.S. Science. 1998; 281: 1680-1683Crossref PubMed Scopus (2581) Google Scholar, 27Wang C.Y. Mayo M.W. Baldwin Jr., A.S. Science. 1996; 274: 784-787Crossref PubMed Scopus (2515) Google Scholar). Thus, in addition to the E8-FLIP and the bcl-2 homologue, the E10/CARMEN gene product of EHV-2 may provide the virus with a third anti-apoptotic mechanism. In addition, NF-κB induction by v-CARMEN may serve to control the expression of viral genes with an NF-κB promotor in the course of viral replication (28Mosialos G. Semin. Cancer Biol. 1997; 8: 121-129Crossref PubMed Scopus (71) Google Scholar). We have identified a cellular homologue and binding partner of v-CARMEN as c-CARMEN, which is highly homologous to the viral protein in its N-terminal CARD motif. v-CARMEN and c-CARMEN interact directly in a CARD-dependent manner yet reveal different binding specificities toward members of the TRAF family. When overexpressed in 293T cells, v-CARMEN is a potent inducer of the JNK, p38, and NF-κB transcriptional pathways, whereas c-CARMEN or truncated versions thereof do not appear to activate these pathways by themselves nor do they affect the JNK and NF-κB activating potential of v-CARMEN. c-CARMEN may therefore act upstream of v-CARMEN in an as yet unidentified NF-κB/JNK-activating pathway. Alternatively, c-CARMEN may interfere with NF-κB/JNK activation only upon a post-translational regulatory event, such as phosphorylation, or upon interaction with a third component lacking in our cellular system. Finally, we cannot exclude the possibility that c-CARMEN mediates yet another NF-κB/JNK-unrelated function of v-CARMEN and that the observed CARD-dependent NF-κB/JNK activation through v-CARMEN is mediated by an as yet unidentified CARD-containing protein. Interestingly, mutation of a novel gene (Bcl10) identical to c-CARMEN was recently reported to be associated with B-cell lymphomas of mucosa-associated lymphoid tissue and other tumor types (29Willis T.G. Jadayel D.M. Du M.-Q. Peng H. Perry A.R. Abdul-Rauf M. Price H. Karran L. Majekodunmi O. Wlodarska I. Pan L. Crook T. Hamoudi R. Isaacson P.G. Dyer M.J.S. Cell. 1999; 96: 35-45Abstract Full Text Full Text PDF PubMed Scopus (572) Google Scholar). Further study of the molecular mechanism of v-CARMEN function may help in the understanding of the physiological role of its cellular homologue and its potential implication in tumor development. We thank Dr. Ralph Budd for careful reading of the manuscript and Jean-Luc Bodmer for help with the submission of sequences to GenBankTM." @default.
• W2000594485 created "2016-06-24" @default.
• W2000594485 creator A5015519563 @default.
• W2000594485 creator A5037493613 @default.
• W2000594485 creator A5045281805 @default.
• W2000594485 creator A5059727262 @default.
• W2000594485 creator A5062448206 @default.
• W2000594485 creator A5063080135 @default.
• W2000594485 creator A5063131503 @default.
• W2000594485 creator A5072397320 @default.
• W2000594485 date "1999-04-01" @default.
• W2000594485 modified "2023-10-16" @default.
• W2000594485 title "Equine Herpesvirus-2 E10 Gene Product, but Not Its Cellular Homologue, Activates NF-κB Transcription Factor and c-Jun N-terminal Kinase" @default.
• W2000594485 cites W1573146315 @default.
• W2000594485 cites W1589267572 @default.
• W2000594485 cites W1965971815 @default.
• W2000594485 cites W1969501356 @default.
• W2000594485 cites W1977077008 @default.
• W2000594485 cites W1980754795 @default.
• W2000594485 cites W1983398917 @default.
• W2000594485 cites W1990735654 @default.
• W2000594485 cites W1992381515 @default.
• W2000594485 cites W1997199912 @default.
• W2000594485 cites W1998585620 @default.
• W2000594485 cites W2002503549 @default.
• W2000594485 cites W2006338784 @default.
• W2000594485 cites W2017985723 @default.
• W2000594485 cites W2033403762 @default.
• W2000594485 cites W2035799757 @default.
• W2000594485 cites W2038212272 @default.
• W2000594485 cites W2043170300 @default.
• W2000594485 cites W2047664746 @default.
• W2000594485 cites W2055588490 @default.
• W2000594485 cites W2064122617 @default.
• W2000594485 cites W2069139760 @default.
• W2000594485 cites W2070479140 @default.
• W2000594485 cites W2082575834 @default.
• W2000594485 cites W2102585554 @default.
• W2000594485 cites W2119683782 @default.
• W2000594485 cites W2120492514 @default.
• W2000594485 cites W2144701362 @default.
• W2000594485 cites W2157086104 @default.
• W2000594485 doi "https://doi.org/10.1074/jbc.274.15.9962" @default.
• W2000594485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10187771" @default.
• W2000594485 hasPublicationYear "1999" @default.
• W2000594485 type Work @default.
• W2000594485 sameAs 2000594485 @default.
• W2000594485 citedByCount "101" @default.
• W2000594485 countsByYear W20005944852012 @default.
• W2000594485 countsByYear W20005944852013 @default.
• W2000594485 countsByYear W20005944852014 @default.
• W2000594485 countsByYear W20005944852015 @default.
• W2000594485 countsByYear W20005944852016 @default.
• W2000594485 countsByYear W20005944852017 @default.
• W2000594485 countsByYear W20005944852018 @default.
• W2000594485 crossrefType "journal-article" @default.
• W2000594485 hasAuthorship W2000594485A5015519563 @default.
• W2000594485 hasAuthorship W2000594485A5037493613 @default.
• W2000594485 hasAuthorship W2000594485A5045281805 @default.
• W2000594485 hasAuthorship W2000594485A5059727262 @default.
• W2000594485 hasAuthorship W2000594485A5062448206 @default.
• W2000594485 hasAuthorship W2000594485A5063080135 @default.
• W2000594485 hasAuthorship W2000594485A5063131503 @default.
• W2000594485 hasAuthorship W2000594485A5072397320 @default.
• W2000594485 hasBestOaLocation W20005944851 @default.
• W2000594485 hasConcept C104317684 @default.
• W2000594485 hasConcept C150194340 @default.
• W2000594485 hasConcept C153911025 @default.
• W2000594485 hasConcept C184235292 @default.
• W2000594485 hasConcept C195286587 @default.
• W2000594485 hasConcept C2779087070 @default.
• W2000594485 hasConcept C2779664074 @default.
• W2000594485 hasConcept C41008148 @default.
• W2000594485 hasConcept C54355233 @default.
• W2000594485 hasConcept C76155785 @default.
• W2000594485 hasConcept C86339819 @default.
• W2000594485 hasConcept C86803240 @default.
• W2000594485 hasConcept C95444343 @default.
• W2000594485 hasConceptScore W2000594485C104317684 @default.
• W2000594485 hasConceptScore W2000594485C150194340 @default.
• W2000594485 hasConceptScore W2000594485C153911025 @default.
• W2000594485 hasConceptScore W2000594485C184235292 @default.
• W2000594485 hasConceptScore W2000594485C195286587 @default.
• W2000594485 hasConceptScore W2000594485C2779087070 @default.
• W2000594485 hasConceptScore W2000594485C2779664074 @default.
• W2000594485 hasConceptScore W2000594485C41008148 @default.
• W2000594485 hasConceptScore W2000594485C54355233 @default.
• W2000594485 hasConceptScore W2000594485C76155785 @default.
• W2000594485 hasConceptScore W2000594485C86339819 @default.
• W2000594485 hasConceptScore W2000594485C86803240 @default.
• W2000594485 hasConceptScore W2000594485C95444343 @default.
• W2000594485 hasIssue "15" @default.
• W2000594485 hasLocation W20005944851 @default.
• W2000594485 hasLocation W20005944852 @default.
• W2000594485 hasOpenAccess W2000594485 @default.
• W2000594485 hasPrimaryLocation W20005944851 @default.
• W2000594485 hasRelatedWork W2009966535 @default.
• W2000594485 hasRelatedWork W2019988726 @default.

• next